METHOD FOR DETERMINING INTENSITY OF ACCUMULATION OF RADIOPHARMACEUTICAL DRUG (RD) IN AREAS CORRESPONDING TO LACHRYMAL PASSAGES, FOR PREDICTING RISK OF SECONDARY LACHRYMAL PASSAGES OBLITERATION IN PATIENTS AFTER RADIOIODINE THERAPY Russian patent published in 2025 - IPC A61B5/107 G01T1/164 

FIELD: medicine.

SUBSTANCE: method of determining accumulation intensity of radiopharmaceutical drug (RD) in areas corresponding to lachrymal passages, by scintigraphic image of the patient's head and neck is based on detection of RD accumulation areas corresponding to lachrymal passages, namely: on scintigraphic image RD accumulation zones are visualized in the left and right submandibular or parotid salivary glands, finding their geometric centers with subsequent selection of the upper and lower boundaries of the desired RD localization areas corresponding to the lachrymal passages, wherein the lower boundary of the location of the desired region is determined at distance of 77.3 ± 6.0 mm from the line connecting the geometrical centers of the zones corresponding to the submandibular salivary glands, OR at distance of 27.6 ± 2.3 mm from the line connecting the geometric centers of the zones corresponding to the parotid salivary glands, and the upper boundary is at distance of 97.1 ± 6.8 mm from the line connecting the centers of the zones corresponding to the submandibular salivary glands, or at 47.4 ± 3.4 mm from the line connecting the centers of the zones corresponding to the parotid salivary glands. If the RD accumulation zones in the parotid or submandibular salivary glands are not determined, the oral or nasal cavity is used as anatomical landmarks and their geometric centers are found. Lower and upper boundary of the location of the desired area is determined by the line perpendicular to the axis of symmetry of the obtained scintigraphic image, where the lower boundary is located at distance of 37.4 ± 3.4 mm from the geometric center of the oral cavity or at distance of 8.5 ± 0.6 mm from the geometric center of the nasal cavity, upper boundary is located at distance of 57.2 ± 4.4 mm from the geometric center of the oral cavity or at distance of 28.3 ± 2.2 mm from the geometric center of the nasal cavity. Intensity of RD accumulation is determined in areas of RD accumulation corresponding to lachrymal passages located within the specified boundaries. Determining the boundaries of the investigated area with a quantitative assessment of the intensity of the RD accumulation affects the construction of a reliable prediction used for taking adequate preventive measures.

EFFECT: invention can be used to determine a risk group of secondary lachrymal passages in patients after radioiodine therapy of thyroid cancer.

1 cl, 1 tbl, 16 dwg